JP2004529904A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004529904A5 JP2004529904A5 JP2002571044A JP2002571044A JP2004529904A5 JP 2004529904 A5 JP2004529904 A5 JP 2004529904A5 JP 2002571044 A JP2002571044 A JP 2002571044A JP 2002571044 A JP2002571044 A JP 2002571044A JP 2004529904 A5 JP2004529904 A5 JP 2004529904A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- dihydroxy
- thiazolyl
- dione
- heptadecane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 69
- 229940124597 therapeutic agent Drugs 0.000 claims 57
- 239000003795 chemical substances by application Substances 0.000 claims 44
- 230000001028 anti-proliverative effect Effects 0.000 claims 38
- 150000001875 compounds Chemical class 0.000 claims 32
- 239000000203 mixture Substances 0.000 claims 31
- -1 R 21 Chemical compound 0.000 claims 30
- 125000000217 alkyl group Chemical group 0.000 claims 29
- 125000000547 substituted alkyl group Chemical group 0.000 claims 25
- 206010028980 Neoplasm Diseases 0.000 claims 13
- 125000003118 aryl group Chemical group 0.000 claims 12
- 229940079593 drug Drugs 0.000 claims 12
- LZWPOLSJFGLQCE-UHFFFAOYSA-N heptadecane-5,9-dione Chemical compound CCCCCCCCC(=O)CCCC(=O)CCCC LZWPOLSJFGLQCE-UHFFFAOYSA-N 0.000 claims 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 11
- 125000003107 substituted aryl group Chemical group 0.000 claims 11
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 11
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 10
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 9
- OADTZFQWKOAHJF-UHFFFAOYSA-N C=1/C(CCCC(CCCCCCCCCC1)=O)=O Chemical compound C=1/C(CCCC(CCCCCCCCCC1)=O)=O OADTZFQWKOAHJF-UHFFFAOYSA-N 0.000 claims 8
- 125000002252 acyl group Chemical group 0.000 claims 8
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 8
- OUSFTKFNBAZUKL-UHFFFAOYSA-N N-(5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-yl)piperidine-4-carboxamide Chemical group O1C(C(C)(C)C)=CN=C1CSC(S1)=CN=C1NC(=O)C1CCNCC1 OUSFTKFNBAZUKL-UHFFFAOYSA-N 0.000 claims 7
- AKEIDJDUUVIOKJ-UHFFFAOYSA-N 13,14,15,15,16-pentamethyl-14-[1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-17-oxa-13-azabicyclo[14.1.0]heptadecane-8,12-dione Chemical compound CN1C(=O)CCCC(=O)CCCCCCC2OC2(C)C(C)(C)C1(C)C(C)=CC1=CSC(C)=N1 AKEIDJDUUVIOKJ-UHFFFAOYSA-N 0.000 claims 6
- 125000003287 1H-imidazol-4-ylmethyl group Chemical group [H]N1C([H])=NC(C([H])([H])[*])=C1[H] 0.000 claims 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 6
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 6
- 229960004316 cisplatin Drugs 0.000 claims 6
- 150000004677 hydrates Chemical class 0.000 claims 6
- 239000012453 solvate Substances 0.000 claims 6
- AADVCYNFEREWOS-UHFFFAOYSA-N (+)-DDM Natural products C=CC=CC(C)C(OC(N)=O)C(C)C(O)C(C)CC(C)=CC(C)C(O)C(C)C=CC(O)CC1OC(=O)C(C)C(O)C1C AADVCYNFEREWOS-UHFFFAOYSA-N 0.000 claims 5
- 108010006654 Bleomycin Proteins 0.000 claims 5
- AADVCYNFEREWOS-OBRABYBLSA-N Discodermolide Chemical compound C=C\C=C/[C@H](C)[C@H](OC(N)=O)[C@@H](C)[C@H](O)[C@@H](C)C\C(C)=C/[C@H](C)[C@@H](O)[C@@H](C)\C=C/[C@@H](O)C[C@@H]1OC(=O)[C@H](C)[C@@H](O)[C@H]1C AADVCYNFEREWOS-OBRABYBLSA-N 0.000 claims 5
- 108090000790 Enzymes Proteins 0.000 claims 5
- 102000004190 Enzymes Human genes 0.000 claims 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 5
- 102000029749 Microtubule Human genes 0.000 claims 5
- 108091022875 Microtubule Proteins 0.000 claims 5
- 229940119336 Microtubule stabilizer Drugs 0.000 claims 5
- 229930192392 Mitomycin Natural products 0.000 claims 5
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 5
- 229940123237 Taxane Drugs 0.000 claims 5
- 241000863480 Vinca Species 0.000 claims 5
- 229940100198 alkylating agent Drugs 0.000 claims 5
- 239000002168 alkylating agent Substances 0.000 claims 5
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 5
- 230000000340 anti-metabolite Effects 0.000 claims 5
- 230000000118 anti-neoplastic effect Effects 0.000 claims 5
- 229940100197 antimetabolite Drugs 0.000 claims 5
- 239000002256 antimetabolite Substances 0.000 claims 5
- 239000003886 aromatase inhibitor Substances 0.000 claims 5
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 5
- 229960001561 bleomycin Drugs 0.000 claims 5
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 229960004562 carboplatin Drugs 0.000 claims 5
- 230000006369 cell cycle progression Effects 0.000 claims 5
- 231100000433 cytotoxic Toxicity 0.000 claims 5
- 230000001472 cytotoxic effect Effects 0.000 claims 5
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims 5
- 229960004679 doxorubicin Drugs 0.000 claims 5
- 229930013356 epothilone Natural products 0.000 claims 5
- 150000003883 epothilone derivatives Chemical class 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 5
- 210000004688 microtubule Anatomy 0.000 claims 5
- 229960004857 mitomycin Drugs 0.000 claims 5
- 229960001156 mitoxantrone Drugs 0.000 claims 5
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims 5
- 239000002777 nucleoside Substances 0.000 claims 5
- 229910052697 platinum Inorganic materials 0.000 claims 5
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 claims 5
- 229960000624 procarbazine Drugs 0.000 claims 5
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- GQBOEYOUQKPVPG-UHFFFAOYSA-N 1-oxacyclohexadec-4-ene-2-carboxamide Chemical compound O1CCCCCCCCCCCC=CCC1C(=O)N GQBOEYOUQKPVPG-UHFFFAOYSA-N 0.000 claims 3
- IBBYOHOCTOFKCY-UHFFFAOYSA-N 2-ethylhexadecanamide Chemical compound CCCCCCCCCCCCCCC(CC)C(N)=O IBBYOHOCTOFKCY-UHFFFAOYSA-N 0.000 claims 3
- 229940046844 aromatase inhibitors Drugs 0.000 claims 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 3
- KLEAIHJJLUAXIQ-JDRGBKBRSA-N irinotecan hydrochloride hydrate Chemical compound O.O.O.Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 KLEAIHJJLUAXIQ-JDRGBKBRSA-N 0.000 claims 3
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 3
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 claims 3
- 230000005855 radiation Effects 0.000 claims 3
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 3
- LBPFLNDUCNNGPS-GNAFDRTKSA-N (3r)-3-benzyl-1-(1h-imidazol-5-ylmethyl)-4-thiophen-2-ylsulfonyl-3,5-dihydro-2h-1,4-benzodiazepine-7-carbonitrile;hydrochloride Chemical compound Cl.C=1C=CSC=1S(=O)(=O)N([C@@H](C1)CC=2C=CC=CC=2)CC2=CC(C#N)=CC=C2N1CC1=CN=CN1 LBPFLNDUCNNGPS-GNAFDRTKSA-N 0.000 claims 2
- 229940122815 Aromatase inhibitor Drugs 0.000 claims 2
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 claims 2
- 150000002118 epoxides Chemical class 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000003147 glycosyl group Chemical group 0.000 claims 2
- 125000003835 nucleoside group Chemical group 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 claims 2
- 229960001237 podophyllotoxin Drugs 0.000 claims 2
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 150000003195 pteridines Chemical class 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- QCSSVGLLBGMHSH-UHFFFAOYSA-N 16-[1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-17-oxa-13-azabicyclo[14.1.0]heptadecane-8,12-dione Chemical compound C1CNC(=O)CCCC(=O)CCCCCCC(O2)C12C(C)=CC1=CSC(C)=N1 QCSSVGLLBGMHSH-UHFFFAOYSA-N 0.000 claims 1
- BLYICQANMCZYKO-UHFFFAOYSA-N 2-[2-[2-(benzyliminomethyl)-1,3-thiazol-4-yl]ethenyl]-1-methyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione Chemical compound CC12C(O1)CCCCCCC(=O)CCCC(=O)OCC2C=CC3=CSC(=N3)C=NCC4=CC=CC=C4 BLYICQANMCZYKO-UHFFFAOYSA-N 0.000 claims 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims 1
- 150000001241 acetals Chemical class 0.000 claims 1
- 229960004117 capecitabine Drugs 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 claims 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 230000003287 optical effect Effects 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27580101P | 2001-03-14 | 2001-03-14 | |
| US31639501P | 2001-08-31 | 2001-08-31 | |
| PCT/US2002/006746 WO2002072085A1 (en) | 2001-03-14 | 2002-03-05 | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004529904A JP2004529904A (ja) | 2004-09-30 |
| JP2004529904A5 true JP2004529904A5 (enExample) | 2005-12-22 |
Family
ID=29254237
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002571044A Pending JP2004529904A (ja) | 2001-03-14 | 2002-03-05 | 増殖性疾患の治療のためのエポシロン類似体および化学療法剤の組み合わせ |
Country Status (25)
| Country | Link |
|---|---|
| US (5) | US7312237B2 (enExample) |
| EP (1) | EP1383490B1 (enExample) |
| JP (1) | JP2004529904A (enExample) |
| KR (1) | KR20040025904A (enExample) |
| CN (1) | CN1496256A (enExample) |
| AT (1) | ATE554756T1 (enExample) |
| AU (1) | AU2002248542B9 (enExample) |
| BG (1) | BG66289B1 (enExample) |
| BR (1) | BRPI0207961B8 (enExample) |
| CA (1) | CA2440555A1 (enExample) |
| CZ (1) | CZ305799B6 (enExample) |
| EE (1) | EE05417B1 (enExample) |
| ES (1) | ES2384789T3 (enExample) |
| HR (1) | HRP20030831B1 (enExample) |
| HU (1) | HU230273B1 (enExample) |
| IL (2) | IL157443A0 (enExample) |
| IS (1) | IS2882B (enExample) |
| MX (1) | MXPA03008135A (enExample) |
| NO (1) | NO333972B1 (enExample) |
| PL (1) | PL368973A1 (enExample) |
| RU (1) | RU2321400C2 (enExample) |
| SK (1) | SK11082003A3 (enExample) |
| TW (1) | TWI330530B (enExample) |
| WO (1) | WO2002072085A1 (enExample) |
| ZA (1) | ZA200307123B (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6242469B1 (en) | 1996-12-03 | 2001-06-05 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
| US6867305B2 (en) | 1996-12-03 | 2005-03-15 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| US6204388B1 (en) * | 1996-12-03 | 2001-03-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| US6605599B1 (en) | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
| US20020058286A1 (en) * | 1999-02-24 | 2002-05-16 | Danishefsky Samuel J. | Synthesis of epothilones, intermediates thereto and analogues thereof |
| NZ526871A (en) | 2001-01-25 | 2006-01-27 | Bristol Myers Squibb Co | Pharmaceutical dosage forms of epothilones for oral administration |
| MXPA03007394A (es) | 2001-02-20 | 2003-12-04 | Bristol Myers Squibb Co | Tratamiento de tumores refractarios mediante uso de derivados de epotilona. |
| TWI315982B (en) | 2001-07-19 | 2009-10-21 | Novartis Ag | Combinations comprising epothilones and pharmaceutical uses thereof |
| CZ2004287A3 (cs) * | 2001-08-31 | 2004-10-13 | Bristol@Myersásquibbácompany | Prostředky a způsoby pro léčení rakoviny |
| MXPA04006822A (es) * | 2002-01-14 | 2004-12-08 | Novartis Ag | Combinaciones que comprenden epotilonas y anti-metabolitos. |
| TW200403994A (en) * | 2002-04-04 | 2004-03-16 | Bristol Myers Squibb Co | Oral administration of EPOTHILONES |
| TW200400191A (en) * | 2002-05-15 | 2004-01-01 | Bristol Myers Squibb Co | Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives |
| AU2003242646A1 (en) * | 2002-06-10 | 2003-12-22 | Novartis Ag | Combinations comprising epothilones and pharmaceutical uses thereof |
| US7008936B2 (en) * | 2002-06-14 | 2006-03-07 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
| EP2186811A1 (en) * | 2002-08-23 | 2010-05-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
| US6921769B2 (en) | 2002-08-23 | 2005-07-26 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| US7649006B2 (en) | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| BR0315169A (pt) * | 2002-10-09 | 2005-08-23 | Kosan Biosciences Inc | Referência cruzada a pedidos de patente relacionados |
| GB0305928D0 (en) * | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| BRPI0414043A (pt) * | 2003-09-02 | 2006-10-24 | Novartis Ag | tratamento de cáncer com epotilonas |
| US20050171167A1 (en) * | 2003-11-04 | 2005-08-04 | Haby Thomas A. | Process and formulation containing epothilones and analogs thereof |
| US20050272722A1 (en) * | 2004-03-18 | 2005-12-08 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
| US20050272068A1 (en) * | 2004-03-18 | 2005-12-08 | The Brigham And Women's Hospital, Inc. | UCH-L1 expression and cancer therapy |
| EP1744751A4 (en) * | 2004-03-18 | 2010-03-10 | Brigham & Womens Hospital | METHOD FOR THE TREATMENT OF SYNUCLEINOPATHIES |
| JP2007529555A (ja) * | 2004-03-18 | 2007-10-25 | ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド | シヌクレイノパチーを治療する方法 |
| US20070293539A1 (en) * | 2004-03-18 | 2007-12-20 | Lansbury Peter T | Methods for the treatment of synucleinopathies |
| US20060106060A1 (en) * | 2004-03-18 | 2006-05-18 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies (Lansbury) |
| US20050215604A1 (en) * | 2004-03-26 | 2005-09-29 | Kosan Biosciences, Inc. | Combination therapies with epothilones and carboplatin |
| US20090004277A1 (en) * | 2004-05-18 | 2009-01-01 | Franchini Miriam K | Nanoparticle dispersion containing lactam compound |
| CA2573949A1 (en) * | 2004-07-26 | 2006-02-02 | Novartis Ag | Epothilone combinations |
| US20060134214A1 (en) * | 2004-11-18 | 2006-06-22 | Ismat Ullah | Enteric coated bead comprising epothilone or epothilone analog, and preparation and administration thereof |
| KR20070084325A (ko) * | 2004-11-18 | 2007-08-24 | 브리스톨-마이어스 스큅 컴퍼니 | 익사베필론을 포함하는 장용성 코팅된 비드 및 그의 제조방법 |
| US20060121511A1 (en) | 2004-11-30 | 2006-06-08 | Hyerim Lee | Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents |
| JP2008536479A (ja) | 2005-02-11 | 2008-09-11 | ユニバーシティ オブ サザン カリフォルニア | ジスルフィド架橋を有するタンパク質の発現法 |
| US20060194821A1 (en) * | 2005-02-18 | 2006-08-31 | The Brigham And Women's Hospital, Inc. | Compounds inhibiting the aggregation of superoxide dismutase-1 |
| WO2006105127A2 (en) | 2005-03-31 | 2006-10-05 | Takeda San Diego, Inc. | Hydroxysteroid dehydrogenase inhibitors |
| US20070190544A1 (en) * | 2005-10-28 | 2007-08-16 | Emory University | Methods of screening for resistance to microtuble-targeting drugs |
| EP1994412A2 (en) | 2006-03-31 | 2008-11-26 | Brystol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents |
| EP2004184A2 (en) * | 2006-04-05 | 2008-12-24 | Novartis AG | Combinations of therapeutic agents for treating cancer |
| EP2029156A4 (en) * | 2006-05-01 | 2010-07-21 | Univ Southern California | COMBINATION THERAPY FOR CANCER TREATMENT |
| CN101732310B (zh) * | 2006-07-12 | 2011-07-20 | 湖南迪诺制药有限公司 | 埃博霉素b的用途 |
| EP2227296B1 (en) * | 2008-01-08 | 2015-11-25 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with tubulin modulating agents for the treatment of proliferative diseases |
| US8232402B2 (en) * | 2008-03-12 | 2012-07-31 | Link Medicine Corporation | Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications |
| US8802394B2 (en) | 2008-11-13 | 2014-08-12 | Radu O. Minea | Method of expressing proteins with disulfide bridges with enhanced yields and activity |
| WO2010057006A1 (en) * | 2008-11-13 | 2010-05-20 | Link Medicine Corporation | Azaquinolinone derivatives and uses thereof |
| US20110060005A1 (en) * | 2008-11-13 | 2011-03-10 | Link Medicine Corporation | Treatment of mitochondrial disorders using a farnesyl transferase inhibitor |
| US20100331363A1 (en) * | 2008-11-13 | 2010-12-30 | Link Medicine Corporation | Treatment of mitochondrial disorders using a farnesyl transferase inhibitor |
| WO2011146638A1 (en) | 2010-05-18 | 2011-11-24 | Cerulean Pharma Inc. | Compositions and methods for treatment of autoimmune and other diseases |
| US8435972B2 (en) * | 2010-09-02 | 2013-05-07 | Emory University | Method for the treatment of central nervous system cancers and compositions related thereto |
| JP2014516075A (ja) | 2011-06-06 | 2014-07-07 | シェブロン フィリップス ケミカル カンパニー エルピー | 癌治療のためのメタロセン化合物の使用 |
| WO2021142202A1 (en) | 2020-01-10 | 2021-07-15 | R-Pharm Us Operating Llc | Compositions of ixabepilone |
| TW202326134A (zh) * | 2021-12-24 | 2023-07-01 | 國立清華大學 | 用於破壞細胞內微管的方法及平台 |
Family Cites Families (156)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4247942A (en) * | 1961-03-01 | 1981-01-27 | Ford Aerospace & Communications Corp. | Jam resistant communication system |
| CH513157A (de) * | 1967-02-27 | 1971-09-30 | Hoffmann La Roche | Verfahren zur Herstellung von Pyrrolinverbindungen |
| US3831013A (en) * | 1973-02-20 | 1974-08-20 | Us Navy | Correlators using shift registers |
| US3900721A (en) * | 1974-02-14 | 1975-08-19 | Us Navy | Serial-access linear transform |
| US4653069A (en) * | 1975-11-06 | 1987-03-24 | General Electric Company | Spread spectrum correlation receiver |
| US4112372A (en) * | 1977-01-11 | 1978-09-05 | Texas Instruments Incorporated | Spread spectrum communication system |
| US4285060A (en) * | 1978-02-28 | 1981-08-18 | Harris Corporation | Spread spectrum code tracking loop |
| US4189677A (en) * | 1978-03-13 | 1980-02-19 | Purdue Research Foundation | Demodulator unit for spread spectrum apparatus utilized in a cellular mobile communication system |
| US4193031A (en) * | 1978-03-13 | 1980-03-11 | Purdue Research Foundation | Method of signal transmission and reception utilizing wideband signals |
| US4222115A (en) * | 1978-03-13 | 1980-09-09 | Purdue Research Foundation | Spread spectrum apparatus for cellular mobile communication systems |
| DE3023375C1 (enExample) * | 1980-06-23 | 1987-12-03 | Siemens Ag, 1000 Berlin Und 8000 Muenchen, De | |
| US4455651A (en) * | 1980-10-20 | 1984-06-19 | Equatorial Communications Company | Satellite communications system and apparatus |
| US4730340A (en) * | 1980-10-31 | 1988-03-08 | Harris Corp. | Programmable time invariant coherent spread symbol correlator |
| US4392232A (en) * | 1981-09-28 | 1983-07-05 | B-Systems, Inc. | Simplified transversal correlator for MSK and MSK related waveforms |
| US4425642A (en) * | 1982-01-08 | 1984-01-10 | Applied Spectrum Technologies, Inc. | Simultaneous transmission of two information signals within a band-limited communications channel |
| US4479226A (en) * | 1982-03-29 | 1984-10-23 | At&T Bell Laboratories | Frequency-hopped single sideband mobile radio system |
| US4563774A (en) * | 1982-10-25 | 1986-01-07 | At&T Bell Laboratories | Address coded communication system |
| US4755983A (en) * | 1983-03-01 | 1988-07-05 | Hazeltine Corporation | Dedicated message matched filter |
| US4512013A (en) * | 1983-04-11 | 1985-04-16 | At&T Bell Laboratories | Simultaneous transmission of speech and data over an analog channel |
| US4523311A (en) * | 1983-04-11 | 1985-06-11 | At&T Bell Laboratories | Simultaneous transmission of speech and data over an analog channel |
| US4538280A (en) * | 1983-05-05 | 1985-08-27 | E-Systems, Inc. | Coherent spread spectrum pseudonoise tracking loop |
| FR2549663A1 (fr) * | 1983-07-21 | 1985-01-25 | Snecma | Procede et dispositif pour le codage et le decodage d'une emission a large bande |
| GB2144310A (en) * | 1983-08-01 | 1985-02-27 | Philips Electronic Associated | Multiple-access communications system |
| US4649549A (en) * | 1983-08-30 | 1987-03-10 | Sophisticated Signals And Circuits | Apparatus for synchronizing linear PN sequences |
| US4641322A (en) * | 1983-10-18 | 1987-02-03 | Nec Corporation | System for carrying out spread spectrum communication through an electric power line |
| JPS60103834A (ja) * | 1983-11-11 | 1985-06-08 | Nippo Tsushin Kogyo Kk | 個人呼出通信システム |
| US4660164A (en) * | 1983-12-05 | 1987-04-21 | The United States Of America As Represented By The Secretary Of The Navy | Multiplexed digital correlator |
| US4672605A (en) * | 1984-03-20 | 1987-06-09 | Applied Spectrum Technologies, Inc. | Data and voice communications system |
| JPS60220635A (ja) * | 1984-04-17 | 1985-11-05 | Clarion Co Ltd | スペクトラム拡散送受信機 |
| DE3427058A1 (de) * | 1984-07-23 | 1986-02-06 | Standard Elektrik Lorenz Ag, 7000 Stuttgart | Empfaenger fuer bandgespreizte signale |
| US4639914A (en) * | 1984-12-06 | 1987-01-27 | At&T Bell Laboratories | Wireless PBX/LAN system with optimum combining |
| DE3447107A1 (de) * | 1984-12-22 | 1986-06-26 | Philips Patentverwaltung Gmbh, 2000 Hamburg | Verfahren zur nachrichtenuebertragung in einem digitalen funkuebertragungssystem |
| GB2171576B (en) * | 1985-02-04 | 1989-07-12 | Mitel Telecom Ltd | Spread spectrum leaky feeder communication system |
| US4675839A (en) * | 1985-04-10 | 1987-06-23 | Allied Corporation | Receiver for a spread spectrum communication system having a time-multiplexed convolver |
| US4742512A (en) * | 1985-07-19 | 1988-05-03 | Nec Corporation | Multipoint communication system having polling and reservation schemes |
| US4672658A (en) * | 1985-10-16 | 1987-06-09 | At&T Company And At&T Bell Laboratories | Spread spectrum wireless PBX |
| US4647863A (en) * | 1985-11-01 | 1987-03-03 | The United States Of America As Represented By The Secretary Of The Army | Saw transition detector for PSK signals |
| US4718080A (en) * | 1985-12-16 | 1988-01-05 | Serrano Arthur L | Microprocessor controlled interface for cellular system |
| US4703474A (en) * | 1986-02-28 | 1987-10-27 | American Telephone And Telegraph Company, At&T Bell Laboratories | Spread spectrum code-division-multiple-access (SS-CDMA) lightwave communication system |
| FR2595889B1 (fr) * | 1986-03-14 | 1988-05-06 | Havel Christophe | Dispositif de controle de puissance d'emission dans une station emettrice-receptrice de radiocommunication |
| JPS6374330A (ja) * | 1986-09-18 | 1988-04-04 | Sony Corp | 無線通信方法及びそれに用いる通信機 |
| JPS6397033A (ja) * | 1986-10-14 | 1988-04-27 | Kenwood Corp | スペクトラム拡散通信方式における同期パルス発生回路 |
| US4901307A (en) * | 1986-10-17 | 1990-02-13 | Qualcomm, Inc. | Spread spectrum multiple access communication system using satellite or terrestrial repeaters |
| US4759034A (en) * | 1986-12-02 | 1988-07-19 | General Research Of Electronics, Inc. | Multi-step spread spectrum communication apparatus |
| US4775995A (en) * | 1986-12-22 | 1988-10-04 | Motorola, Inc. | Adaptive splatter control |
| US4932037A (en) * | 1987-02-11 | 1990-06-05 | Hillier Technologies Limited Partnership | Remote control system, components and methods |
| JP2624964B2 (ja) * | 1987-06-09 | 1997-06-25 | キヤノン株式会社 | 無線通信装置 |
| US4799253A (en) * | 1987-07-20 | 1989-01-17 | Motorola, Inc. | Colocated cellular radiotelephone systems |
| US4899364A (en) * | 1987-07-31 | 1990-02-06 | Clarion Co., Ltd. | Automatic gain control system |
| US4850036A (en) * | 1987-08-21 | 1989-07-18 | American Telephone And Telegraph Company | Radio communication system using synchronous frequency hopping transmissions |
| US4894842A (en) * | 1987-10-15 | 1990-01-16 | The Charles Stark Draper Laboratory, Inc. | Precorrelation digital spread spectrum receiver |
| US4922506A (en) * | 1988-01-11 | 1990-05-01 | Sicom Corporation | Compensating for distortion in a communication channel |
| US4805208A (en) * | 1988-01-15 | 1989-02-14 | Niravoice, Inc. | Modem compression system for telephone network |
| US4914651A (en) * | 1988-09-20 | 1990-04-03 | Cellular Data, Inc. | Cellular data system |
| EP0369923B1 (fr) * | 1988-11-15 | 1993-09-15 | José Vidal Sans | Dipositif obturateur pour le contrôle d'iléo-colostomies |
| US4930140A (en) * | 1989-01-13 | 1990-05-29 | Agilis Corporation | Code division multiplex system using selectable length spreading code sequences |
| JPH07120968B2 (ja) * | 1989-02-07 | 1995-12-20 | クラリオン株式会社 | スペクトラム拡散通信装置 |
| JP2718978B2 (ja) * | 1989-03-02 | 1998-02-25 | 株式会社トキメック | データ伝送方式 |
| US4993021A (en) * | 1989-03-23 | 1991-02-12 | Telettra-Telefonia Elettronica E Radio Spa | Automatic transmit power level control in radio links |
| US4991164A (en) * | 1989-03-23 | 1991-02-05 | Telettra-Telefonia Elettronica E Radio S.P.A. | Automatic transmit power level control in radio links |
| JP2769478B2 (ja) * | 1989-04-10 | 1998-06-25 | 三菱電機株式会社 | 無線機 |
| JP2720076B2 (ja) * | 1989-07-17 | 1998-02-25 | 京セラ株式会社 | 直接スペクトラム拡散受信機の自動校正装置 |
| US5016255A (en) * | 1989-08-07 | 1991-05-14 | Omnipoint Data Company, Incorporated | Asymmetric spread spectrum correlator |
| US5022047A (en) * | 1989-08-07 | 1991-06-04 | Omnipoint Data Corporation | Spread spectrum correlator |
| US5016256A (en) * | 1989-10-17 | 1991-05-14 | Stewart Clarence H | Spread spectrum intercept apparatus and method |
| US5056109A (en) * | 1989-11-07 | 1991-10-08 | Qualcomm, Inc. | Method and apparatus for controlling transmission power in a cdma cellular mobile telephone system |
| US5109390A (en) * | 1989-11-07 | 1992-04-28 | Qualcomm Incorporated | Diversity receiver in a cdma cellular telephone system |
| US5101501A (en) * | 1989-11-07 | 1992-03-31 | Qualcomm Incorporated | Method and system for providing a soft handoff in communications in a cdma cellular telephone system |
| US5257283A (en) * | 1989-11-07 | 1993-10-26 | Qualcomm Incorporated | Spread spectrum transmitter power control method and system |
| US5005169A (en) * | 1989-11-16 | 1991-04-02 | Westinghouse Electric Corp. | Frequency division multiplex guardband communication system for sending information over the guardbands |
| US5073900A (en) * | 1990-03-19 | 1991-12-17 | Mallinckrodt Albert J | Integrated cellular communications system |
| JP2748656B2 (ja) * | 1990-06-19 | 1998-05-13 | ソニー株式会社 | 移動無線通信方法 |
| US5103459B1 (en) * | 1990-06-25 | 1999-07-06 | Qualcomm Inc | System and method for generating signal waveforms in a cdma cellular telephone system |
| US5040238A (en) * | 1990-06-29 | 1991-08-13 | Motorola, Inc. | Trunking system communication resource reuse method |
| US5129098A (en) * | 1990-09-24 | 1992-07-07 | Novatel Communication Ltd. | Radio telephone using received signal strength in controlling transmission power |
| US5093840A (en) * | 1990-11-16 | 1992-03-03 | Scs Mobilecom, Inc. | Adaptive power control for a spread spectrum transmitter |
| US5299226A (en) * | 1990-11-16 | 1994-03-29 | Interdigital Technology Corporation | Adaptive power control for a spread spectrum communications system and method |
| DE4138042C2 (de) | 1991-11-19 | 1993-10-14 | Biotechnolog Forschung Gmbh | Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel |
| FR2697752B1 (fr) | 1992-11-10 | 1995-04-14 | Rhone Poulenc Rorer Sa | Compositions antitumorales contenant des dérivés du taxane. |
| US5396516A (en) * | 1993-02-22 | 1995-03-07 | Qualcomm Incorporated | Method and system for the dynamic modification of control paremeters in a transmitter power control system |
| US6441026B1 (en) | 1993-11-08 | 2002-08-27 | Aventis Pharma S.A. | Antitumor compositions containing taxane derivatives |
| DE19542986A1 (de) | 1995-11-17 | 1997-05-22 | Biotechnolog Forschung Gmbh | Epothilon-Derivate und deren Verwendung |
| US6288237B1 (en) | 1995-11-17 | 2001-09-11 | Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) | Epothilons C and D, preparation and compositions |
| DE19639456A1 (de) | 1996-09-25 | 1998-03-26 | Biotechnolog Forschung Gmbh | Epothilon-Derivate, Herstellung und Mittel |
| US5758687A (en) * | 1996-05-13 | 1998-06-02 | Funicello; John C. | Dual arm overhead air supply system |
| DE19645361A1 (de) | 1996-08-30 | 1998-04-30 | Ciba Geigy Ag | Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II |
| NZ334821A (en) | 1996-08-30 | 2000-12-22 | Novartis Ag | Method for producing epothilones |
| DE19636343C1 (de) | 1996-08-30 | 1997-10-23 | Schering Ag | Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B |
| DE19645362A1 (de) | 1996-10-28 | 1998-04-30 | Ciba Geigy Ag | Verfahren zur Herstellung von Epothilon A und B und Derivaten |
| CN100344627C (zh) | 1996-11-18 | 2007-10-24 | 生物技术研究有限公司(Gbf) | 埃坡霉素c、其制备方法以及作为细胞抑制剂和植物保护剂的应用 |
| US6515016B2 (en) | 1996-12-02 | 2003-02-04 | Angiotech Pharmaceuticals, Inc. | Composition and methods of paclitaxel for treating psoriasis |
| US6204388B1 (en) | 1996-12-03 | 2001-03-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| US6242469B1 (en) | 1996-12-03 | 2001-06-05 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
| US6867305B2 (en) * | 1996-12-03 | 2005-03-15 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| US6380394B1 (en) | 1996-12-13 | 2002-04-30 | The Scripps Research Institute | Epothilone analogs |
| US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
| DE19701758A1 (de) | 1997-01-20 | 1998-07-23 | Wessjohann Ludgar A Dr | Epothilone-Synthesebausteine |
| NZ337195A (en) | 1997-02-25 | 2001-05-25 | Biotechnolog Forschung Gmbh | Epothilones with a modified side chain |
| DE19713970B4 (de) | 1997-04-04 | 2006-08-31 | R&D-Biopharmaceuticals Gmbh | Epothilone-Synthesebausteine II - Prenylderivate |
| DE59805900D1 (de) | 1997-04-18 | 2002-11-14 | Studiengesellschaft Kohle Mbh | Selektive olefinmetathese von bi- oder polyfunktionellen substraten in komprimiertem kohlendioxid als reaktionsmedium |
| DE19720312A1 (de) | 1997-05-15 | 1998-11-19 | Hoechst Ag | Zubereitung mit erhöhter in vivo Verträglichkeit |
| DE19821954A1 (de) | 1997-05-15 | 1998-11-19 | Biotechnolog Forschung Gmbh | Verfahren zur Herstellung eines Epothilon-Derivats |
| DE19726627A1 (de) | 1997-06-17 | 1998-12-24 | Schering Ag | Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon |
| US6605599B1 (en) | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
| DK1001951T3 (da) | 1997-07-16 | 2002-12-23 | Schering Ag | Thiazolderivater, fremgangsmåde til fremstilling deraf og anvendelse af disse |
| AU9340998A (en) | 1997-08-09 | 1999-03-01 | Schering Aktiengesellschaft | New epothilone derivatives, method for producing same and their pharmaceutical use |
| US6162804A (en) | 1997-09-26 | 2000-12-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| US6262096B1 (en) | 1997-11-12 | 2001-07-17 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
| US6365749B1 (en) | 1997-12-04 | 2002-04-02 | Bristol-Myers Squibb Company | Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs |
| EP1052974B1 (en) | 1998-02-05 | 2009-05-20 | Novartis AG | Pharmaceutical formulation containing epothilone |
| US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
| FR2775187B1 (fr) | 1998-02-25 | 2003-02-21 | Novartis Ag | Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo |
| ATE307123T1 (de) | 1998-02-25 | 2005-11-15 | Sloan Kettering Inst Cancer | Synthese von epothilonen, ihren zwischenprodukten und analogen verbindungen |
| US6399638B1 (en) | 1998-04-21 | 2002-06-04 | Bristol-Myers Squibb Company | 12,13-modified epothilone derivatives |
| US6498257B1 (en) | 1998-04-21 | 2002-12-24 | Bristol-Myers Squibb Company | 2,3-olefinic epothilone derivatives |
| AU5036999A (en) | 1998-06-30 | 2000-01-17 | Schering Aktiengesellschaft | Epothilon derivatives, their preparation process, intermediate products and their pharmaceutical use |
| US6326390B1 (en) * | 1998-08-25 | 2001-12-04 | King Pharmaceuticals Reseach And Development, Inc. | Use of adenosine A3 receptor antagonists to inhibit tumor growth |
| EP1135470A2 (en) | 1998-11-20 | 2001-09-26 | Kosan Biosciences, Inc. | Recombinant methods and materials for producing epothilone and epothilone derivatives |
| EP1140944B1 (en) | 1998-12-22 | 2003-08-27 | Novartis AG | Epothilone derivatives and their use as antitumor agents |
| JP2002533404A (ja) | 1998-12-23 | 2002-10-08 | ジー・ディー・サール・アンド・カンパニー | 新生物形成の治療における組合わせ療法としてインテグリン拮抗剤及び放射線治療を使用する方法 |
| US6780620B1 (en) | 1998-12-23 | 2004-08-24 | Bristol-Myers Squibb Company | Microbial transformation method for the preparation of an epothilone |
| US20030191162A1 (en) | 1998-12-31 | 2003-10-09 | Sugen Inc. | 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy |
| EP1139754A4 (en) | 1998-12-31 | 2002-12-18 | Sugen Inc | 3-HETEROARYLIDENYL-2-INDOLINONE COMPOUNDS FOR MODULATION OF PROTEIN KINASE ACTIVITY AND IN CANCER CHEMOTHERAPY |
| DE19908760A1 (de) * | 1999-02-18 | 2000-08-24 | Schering Ag | Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung |
| CZ20012951A3 (cs) | 1999-02-18 | 2001-11-14 | Schering Aktiengesellschaft | 16-Halogensubstituované deriváty epothilonu, způsoby jejich výroby a jejich farmaceutické pouľití |
| ATE254615T1 (de) | 1999-02-22 | 2003-12-15 | Biotechnolog Forschung Gmbh | C-21 modifizierte epothilone |
| US6211412B1 (en) | 1999-03-29 | 2001-04-03 | The University Of Kansas | Synthesis of epothilones |
| GB9909925D0 (en) | 1999-04-29 | 1999-06-30 | Pharmacia & Upjohn Spa | Combined preparations comprising anthracycline derivatives |
| PE20010116A1 (es) | 1999-04-30 | 2001-02-15 | Schering Ag | Derivados de 6-alquenil-, 6-alquinil- y 6-epoxi-epotilona, procedimientos para su preparacion |
| US6982265B1 (en) | 1999-05-21 | 2006-01-03 | Bristol Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
| DE69934259T2 (de) | 1999-07-23 | 2007-05-31 | Glaxo Group Ltd., Greenford | Kombination von einem Anti-Ep-CAM-Antikörper mit einem chemotherapeutischen Mittel |
| WO2001034133A2 (en) | 1999-11-11 | 2001-05-17 | Eli Lilly And Company | Oncolytic combinations for the treatment of cancer |
| EP1259234B9 (en) | 1999-12-30 | 2007-02-14 | Sugen, Inc. | 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy |
| US6280395B1 (en) * | 2000-01-19 | 2001-08-28 | Mpr Health Systems, Inc. | System and method for determining muscle dysfunction |
| AU2001243372A1 (en) * | 2000-03-01 | 2001-09-12 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| US6593115B2 (en) | 2000-03-24 | 2003-07-15 | Bristol-Myers Squibb Co. | Preparation of epothilone intermediates |
| TWI310684B (en) | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
| US6589968B2 (en) | 2001-02-13 | 2003-07-08 | Kosan Biosciences, Inc. | Epothilone compounds and methods for making and using the same |
| US6462017B1 (en) | 2000-05-01 | 2002-10-08 | Sciclone Pharmaceuticals, Inc. | Method of reducing side effects of chemotherapy in cancer patients |
| UA75365C2 (en) | 2000-08-16 | 2006-04-17 | Bristol Myers Squibb Co | Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon |
| AR033680A1 (es) | 2000-08-30 | 2004-01-07 | Schering Corp | Compuestos triciclicos utiles como inhibidores de la farnesil proteino transferasa y su uso para la manufactura de medicamentos como agentes antitumorales |
| WO2002039958A2 (en) | 2000-11-03 | 2002-05-23 | Tularik Inc. | Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents |
| US20020147198A1 (en) * | 2001-01-12 | 2002-10-10 | Guoqing Chen | Substituted arylamine derivatives and methods of use |
| US6828452B2 (en) | 2001-01-18 | 2004-12-07 | Cognis Deutschland Gmbh & Co. Kg | Method for producing acyl amino acids |
| NZ526871A (en) | 2001-01-25 | 2006-01-27 | Bristol Myers Squibb Co | Pharmaceutical dosage forms of epothilones for oral administration |
| CN1489466A (zh) | 2001-01-25 | 2004-04-14 | ����˹�ж�-����˹˹������˾ | 包含埃博霉素类似物的非肠道制剂 |
| EP1353668B1 (en) | 2001-01-25 | 2008-03-19 | Bristol-Myers Squibb Company | Processes for the preparation of pharmaceutical preparations containing epothilone analogues for the treatment of cancer |
| US6548531B2 (en) | 2001-02-09 | 2003-04-15 | Hoffmann-La Roche Inc. | Method for cancer therapy |
| MXPA03007394A (es) | 2001-02-20 | 2003-12-04 | Bristol Myers Squibb Co | Tratamiento de tumores refractarios mediante uso de derivados de epotilona. |
| CN1610549A (zh) | 2001-02-20 | 2005-04-27 | 布里斯托尔-迈尔斯斯奎布公司 | 用于治疗难治肿瘤的埃坡霉素衍生物 |
| DE60232719D1 (de) | 2001-02-27 | 2009-08-06 | Novartis Ag | Kombination enthaltend einen inhibitor der signaltransduktion und ein epothilonderivat |
| WO2002074042A2 (en) | 2001-03-19 | 2002-09-26 | Novartis Ag | Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative |
| CN100338041C (zh) | 2001-05-03 | 2007-09-19 | 霍夫曼-拉罗奇有限公司 | 明胶酶抑制剂与抗肿瘤剂的组合以及其应用 |
| US6680306B2 (en) | 2001-06-21 | 2004-01-20 | Glycogenesys, Inc. | Method for enhancing the effectiveness of cancer therapies |
| TWI315982B (en) | 2001-07-19 | 2009-10-21 | Novartis Ag | Combinations comprising epothilones and pharmaceutical uses thereof |
| MXPA04006822A (es) | 2002-01-14 | 2004-12-08 | Novartis Ag | Combinaciones que comprenden epotilonas y anti-metabolitos. |
-
2002
- 2002-03-05 CA CA002440555A patent/CA2440555A1/en not_active Abandoned
- 2002-03-05 WO PCT/US2002/006746 patent/WO2002072085A1/en not_active Ceased
- 2002-03-05 ES ES02717548T patent/ES2384789T3/es not_active Expired - Lifetime
- 2002-03-05 HU HU0400203A patent/HU230273B1/hu not_active IP Right Cessation
- 2002-03-05 US US10/091,061 patent/US7312237B2/en not_active Expired - Lifetime
- 2002-03-05 KR KR10-2003-7011867A patent/KR20040025904A/ko not_active Withdrawn
- 2002-03-05 SK SK1108-2003A patent/SK11082003A3/sk unknown
- 2002-03-05 BR BRPI0207961-5 patent/BRPI0207961B8/pt not_active IP Right Cessation
- 2002-03-05 HR HRP20030831AA patent/HRP20030831B1/xx not_active IP Right Cessation
- 2002-03-05 EP EP02717548A patent/EP1383490B1/en not_active Expired - Lifetime
- 2002-03-05 CN CNA028065719A patent/CN1496256A/zh active Pending
- 2002-03-05 AU AU2002248542A patent/AU2002248542B9/en not_active Ceased
- 2002-03-05 PL PL02368973A patent/PL368973A1/xx not_active Application Discontinuation
- 2002-03-05 CZ CZ2003-2376A patent/CZ305799B6/cs not_active IP Right Cessation
- 2002-03-05 RU RU2003130377/14A patent/RU2321400C2/ru not_active IP Right Cessation
- 2002-03-05 IL IL15744302A patent/IL157443A0/xx unknown
- 2002-03-05 EE EEP200300440A patent/EE05417B1/xx not_active IP Right Cessation
- 2002-03-05 MX MXPA03008135A patent/MXPA03008135A/es active IP Right Grant
- 2002-03-05 AT AT02717548T patent/ATE554756T1/de active
- 2002-03-05 JP JP2002571044A patent/JP2004529904A/ja active Pending
- 2002-03-08 TW TW091104423A patent/TWI330530B/zh not_active IP Right Cessation
-
2003
- 2003-08-18 IL IL157443A patent/IL157443A/en not_active IP Right Cessation
- 2003-08-28 BG BG108137A patent/BG66289B1/en unknown
- 2003-09-11 ZA ZA2003/07123A patent/ZA200307123B/en unknown
- 2003-09-12 NO NO20034056A patent/NO333972B1/no not_active IP Right Cessation
- 2003-09-12 IS IS6950A patent/IS2882B/is unknown
-
2004
- 2004-05-20 US US10/850,072 patent/US8569347B2/en active Active
- 2004-12-10 US US11/009,579 patent/US20050159461A1/en not_active Abandoned
-
2009
- 2009-07-23 US US12/508,100 patent/US8598215B2/en not_active Expired - Lifetime
-
2010
- 2010-10-18 US US12/906,511 patent/US20110033457A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004529904A5 (enExample) | ||
| RU2003130377A (ru) | Комбинация аналогов эпотилона и химиотерапевтических агентов для лечения пролиферативных заболеваний | |
| RU2003128312A (ru) | Производные эпотилона, используемые для лечения резистентных опухлей | |
| CA2360452A1 (en) | C-21 modified epothilones | |
| USRE41393E1 (en) | Treatment of refractory tumors using epothilone derivatives | |
| JP2004522774A5 (enExample) | ||
| US6719540B2 (en) | C3-cyano epothilone derivatives | |
| JP2003528864A5 (enExample) | ||
| JP2005527576A5 (enExample) | ||
| US20040019088A1 (en) | Use of Epothilones in the treatment of brain diseases associated with proliferative processes | |
| US7211593B2 (en) | C12-cyano epothilone derivatives | |
| ZA200106039B (en) | C-21 modifier epothilones. | |
| KR20090087038A (ko) | 골다공증 및 관련 질환의 치료에서의 에포틸론의 용도 | |
| EP1640004A1 (en) | Use of epothilones in the treatment of bone metastases and bone tumors or cancers | |
| US20060069136A1 (en) | Use of Epothilones in the treatment of bone metastasis | |
| RU2006136089A (ru) | Производные эпотилона | |
| JP2007529455A5 (enExample) | ||
| AU2002255539A1 (en) | Epothilone derivatives for the treatment of refractory tumors |